Northern Trust Corp Has $90.86 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Northern Trust Corp grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 492,218 shares of the medical research company's stock after buying an additional 58,398 shares during the quarter. Northern Trust Corp owned 0.96% of Charles River Laboratories International worth $90,863,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Fiduciary Financial Group LLC increased its holdings in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Cornerstone Investment Partners LLC grew its holdings in Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after purchasing an additional 69 shares in the last quarter. Metis Global Partners LLC lifted its holdings in Charles River Laboratories International by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after buying an additional 72 shares in the last quarter. Finally, Two Sigma Securities LLC boosted its position in Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after buying an additional 81 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

CRL stock traded down $2.52 during trading on Friday, reaching $138.84. 920,260 shares of the company's stock were exchanged, compared to its average volume of 966,631. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The firm has a market cap of $6.82 billion, a PE ratio of 925.60, a P/E/G ratio of 4.54 and a beta of 1.50. The company's fifty day moving average price is $138.40 and its 200-day moving average price is $166.32. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.27 earnings per share. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the topic of several analyst reports. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a report on Thursday. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $176.00.

Insider Activity

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).